Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials

Future Microbiology

Volumn 5, Issue 6, 2010, Pages 961-970

  Samonis, George ^a   Maraki, Sofia ^a   Rafailidis, Petros I ^b,c   Kapaskelis, Anastasios ^b,c   Kastoris, Antonia C ^b   Falagas, Matthew E ^b,c,d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter baumannii; Antimicrobial resistance; Drug resistance; Extendedspectrum b lactamases; Fosfomycin

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GREECE; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; NONHUMAN; OUTPATIENT; PEDIATRIC WARD; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SALMONELLA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; FOSFOMYCIN; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GREECE; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

ACINETOBACTER BAUMANNII; BACILLI (CLASS); ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SALMONELLA;

EID: 77953273374     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.47     Document Type: Article

References (27)

1. Levy SB, Marshall B: Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10(12 Suppl.), S122-S129 (2004).
2. Falagas ME, Karveli EA: The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin. Microbiol. Infect. 13(2), 117-119 (2007).
3. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A: Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents 32(5), 450-454 (2008).
4. Karageorgopoulos DE, Falagas ME: Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8(12), 751-762 (2008).
5. Bratu S, Landman D, Haag R et al.: Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165(12), 1430-1435 (2005).
6. Falagas ME, Rafailidis PI, Kofteridis D et al.: Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J. Antimicrob. Chemother. 60(5), 1124-1130 (2007).
7. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE: Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum b-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect. Dis. 10(1), 43-50 (2010).
8. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP: Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7), 885-888 (2003).
9. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al.: Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. Infect. Dis. 27(6), 439-443 (2008).
10. Patel SS, Balfour JA, Bryson HM: Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 53(4), 637-656 (1997).
11. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI: Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46(7), 1069-1077 (2008).
12. Thomson RBJ: Specimen collection, transport and processing: bacteriology. In: Manual of Clinical Microbiology (9th Edition). Murray P, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (Eds). American Society for Microbiology, Washington DC, USA, 291-333 (2007).
13. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A9. CLSI, Wayne, PA, USA (2006).
14. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI Document M100-S18. Wayne, PA, USA (2008).
15. Endimiani A, Patel G, Hujer KM et al: In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54(1), 526-529 (2010).
16. Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME: Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob. Agents Chemother. 53(10), 4508-4510 (2009).
17. Tharavichitkul P, Khantawa B, Bousoung V, Boonchoo M: Activity of fosfomycin against extended-spectrum b-lactamase-producing Klebsiella pneumoniae and Escherichia coli in Maharaj Nakorn Chiang Mai Hospital. J. Infect. Dis. Antimicrob. Agents 22(3), 121-126 (2005).
18. de Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A: In vitro activity of fosfomycin against extended-spectrum-b-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob. Agents Chemother. 50(1), 368-370 (2006). (Pubitemid 43042949)
19. Waiwarawooth J, Jutiworakul K, Joraka W: The prevalence and susceptibility patterns of ESBL-producing Klebsiella pneumoniae and Escherichia coli in Chonburi Hospital. J. Infect. Dis. Antimicrob. Agents 23(2), 57-65 (2006).
20. Bert F, Lambert-Zechovsky N: Comparative distribution of resistance patterns and serotypes in Pseudomonas aeruginosa isolates from intensive care units and other wards. J. Antimicrob. Chemother. 37(4), 809-813 (1996).
21. Cavallo JD, Leblanc F, Fabre R: Surveillance of Pseudomonas aeruginosa sensitivity to antibiotics in France and distribution of b-lactam resistance mechanisms: 1998 GERPB study. Pathol. Biol. (Paris) 48(5), 472-477 (2000).
22. Okazaki M, Suzuki K, Asano N et al.: Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J. Infect. Chemother. 8(1), 37-42 (2002).
23. Tessier F, Quentin C: In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 16(2), 159-162 (1997).
24. Dobrewski R, Savov E, Bernards AT et al.: Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin. Microbiol. Infect. 12(11), 1135-1137 (2006).
25. Martinez-Martinez L, Rodriguez G, Pascual A, Suarez AI, Perea EJ: In vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 38(6), 1107-1108 (1996).
26. Nagano N, Nagano Y, Cordevant C, Shibata N, Arakawa Y: Nosocomial transmission of CTX-M-2 b-lactamase-producing Acinetobacter baumannii in a neurosurgery ward. J. Clin. Microbiol. 42(9), 3978-3984 (2004).
27. Falagas ME, Mourtzoukou EG, Polemis M, Vatopoulos AC: Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications. Clin. Microbiol. Infect. 13(8), 816-819 (2007).